On February 12, 2020 Cerus Corporation (Nasdaq:CERS) reported that its fourth quarter and full year 2019 financial results will be released on Thursday, February 20, 2020, after the close of the stock market (Press release, Cerus, FEB 12, 2020, View Source [SID1234554203]). The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast, please visit the Investor Relations page of the Cerus website at View Source Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international).

A replay will be available on the company’s website, or by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and entering conference ID number 9268122. The replay will be available approximately three hours after the call through March 5, 2020.

On February 12, 2020 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported that it will webcast management presentations as follows (Press release, Regeneron, FEB 12, 2020, View Source [SID1234554240]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SVB Leerink 9th Annual Global Healthcare Conference at 10:00 a.m. ET on Tuesday, February 25, 2020
Cowen 40th Annual Healthcare Conference at 1:30 p.m. ET on Monday, March 2, 2020
Barclays Global Healthcare Conference at 4:50 p.m. ET on Tuesday, March 10, 2020
The sessions may be accessed from the "Investors & Media" page of Regeneron’s website at View Source Replays of the webcasts will be archived on the Company’s website for at least 30 days.

On February 12, 2020 Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, reported that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at NobleCon16 – Noble Capital Markets’ 16th Annual Investor Conference on Monday, February 17th at 11:30 a.m. ET in Hollywood, Florida (Press release, AEterna Zentaris, FEB 12, 2020, View Source [SID1234554204]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of his presentation, Dr. Paulini will provide a corporate overview and update on the Company’s lead product, Macrilen (macimorelin), the only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Dr. Paulini’s slide presentation will be made available on the Company’s website on Monday, February 17th.

In addition to the presentation, management will be available to participate in investor meetings with registered qualified investors attending the conference. To request a meeting, please contact the NobleCon16 one-on-one desk

On February 12, 2020 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported that the company plans to present at the following conferences (Press release, Iovance Biotherapeutics, FEB 12, 2020, View Source [SID1234554224]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Healthcare Talks | Oncology Day in New York, Feb. 13, 2020
Date/Time: Thursday, Feb. 13, at 2:00 p.m. EST
Webcast: a live and archived webcast of the presentation will be available in the Investors section of the Iovance website at View Source

SVB Leerink 9th Annual Global Healthcare Conference in New York, Feb. 25-27, 2020
Date/Time: Wednesday, Feb. 26, at 3:00 p.m. EST
Webcast: a live and archived webcast of the presentation will be available in the Investors section of the Iovance website at View Source

6th Annual Immuno-Oncology 360° conference in New York, Feb. 26-28, 2020
Presentation Title: Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer
Date/Time: Thursday, Feb. 27, at 12:00 p.m. EST

On February 12, 2020 GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, reported unaudited results for the year ended 31 December 2019 (Press release, GC Pharma, FEB 12, 2020, View Source [SID1234554241]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Full Year 2019(2)

Growth(2)

Total revenues

KRW 1,369.7 billion

+2.6%

Operating profit

KRW 40.3 billion

(19.7%)

K-IFRS profit after taxation

KRW -11.3 billion

–

(1) Consolidated
(2) Results and percentages compared to the full financial year 2018

Financial Highlights

Delivered total revenue growth of 2.6% KRW 1.37 trillion (2018: KRW 1.33 trillion), all consolidated entities revenues grew plus compared to equivalent 2018 period.
Operating profit decreased 19.7% to KRW 40.3 billion (2018: KRW 41.9 billion), primarily due to an impact of investment in R&D and SG&A.
One off costs – including corporate tax bill and VAT result in regular tax investigation, evaluation loss of stock investment, impairment losses of tangible asset and penalties from local antitrust regulator related to subsidiary, Green Cross MS, and impairment losses of intangible assets – impacted on after tax profits, expected to progressively ease over the course of 2020.